Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

This study is currently recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Prostate Cancer
2		Additional conditions recognized in this trial
			Prostatic Neoplasms
3		More general conditions related to this trial
			Genital Diseases, Male
			Genital Neoplasms, Male
			Neoplasms
			Neoplasms by Site
			Prostatic Diseases
			Urogenital Neoplasms
4		Interventions listed in this trial
			etoposide
			mitoxantrone hydrochloride
			prednisone
			vinorelbine ditartrate
5		Additional drug interventions recognized in this trial
			Mitoxantrone
			Vinblastine
			Vinorelbine
6		More general drug interventions related to this trial
			Analgesics
			Anti-Inflammatory Agents
			Antimitotic Agents
			Antineoplastic Agents
			Antineoplastic Agents, Hormonal
			Antineoplastic Agents, Phytogenic
			Central Nervous System Agents
			Glucocorticoids
			Hormones
			Hormones, Hormone Substitutes, and Hormone Antagonists
			Mitosis Modulators
			Molecular Mechanisms of Pharmacological Action
			Peripheral Nervous System Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Sensory System Agents
			Therapeutic Uses
			Tubulin Modulators
7		Sponsors listed in this trial
			Groupe D'Etude des Tumeurs Uro-Genitales